



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Mostafa M. Bahaa,  
✉ mbahaa@horus.edu.eg

RECEIVED 13 July 2024  
ACCEPTED 20 August 2024  
PUBLISHED 29 August 2024

## CITATION

Aldossary KM, Saad Ali L, Abdallah MS, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, Elmorsi YM, Kamel MM, Negm WA, Elberri AI, Hamouda AO, AlRasheed HA, Salahuddin MM, Yasser M and Hamouda MA (2024) Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study. *Front. Pharmacol.* 15:1464358. doi: 10.3389/fphar.2024.1464358

## COPYRIGHT

© 2024 Aldossary, Saad Ali, Abdallah, Bahaa, Elmasry, Elberri, Kotkata, El Sabaa, Elmorsi, Kamel, Negm, Elberri, Hamouda, AlRasheed, Salahuddin, Yasser and Hamouda. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study

Khlood Mohammad Aldossary<sup>1</sup>, Lashin Saad Ali<sup>2,3</sup>, Mahmoud S. Abdallah<sup>4,5</sup>, Mostafa M. Bahaa<sup>6\*</sup>, Thanaa A. Elmasry<sup>7</sup>, Eman I. Elberri<sup>8</sup>, Fedaa A. Kotkata<sup>8</sup>, Ramy M. El Sabaa<sup>9</sup>, Yasmine M. Elmorsi<sup>8</sup>, Mostafa M. Kamel<sup>10</sup>, Walaa A. Negm<sup>11</sup>, Aya Ibrahim Elberri<sup>12</sup>, Amir O. Hamouda<sup>13</sup>, Hayam Ali AlRasheed<sup>1</sup>, Muhammed M. Salahuddin<sup>13</sup>, Mohamed Yasser<sup>14,15</sup> and Manal A. Hamouda<sup>9</sup>

<sup>1</sup>Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia, <sup>2</sup>Department of Basic Medical Science, Faculty of Dentistry, Al-Ahliyya Amman University, Amman, Jordan, <sup>3</sup>Physiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt, <sup>4</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, Menoufia, Egypt, <sup>5</sup>Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan, <sup>6</sup>Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt, <sup>7</sup>Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt, <sup>8</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt, <sup>9</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Menoufia, Egypt, <sup>10</sup>Psychiatry Department, Faculty of Medicine, Tanta University, Egypt, <sup>11</sup>Pharmacognosy Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt, <sup>12</sup>Genetic Engineering and Molecular Biology Division, Department of Zoology, Faculty of Science, Menoufia University, Shebin El-Kom, Menoufia, Egypt, <sup>13</sup>Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Horus University, New Damietta, Egypt, <sup>14</sup>Department of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said, Egypt, <sup>15</sup>Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Horus University, New Damietta, Egypt

## KEYWORDS

atorvastatin, major depressive disorder, neuroinflammation, NLRP-3, STAT-3

## A Corrigendum on

Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study

by Aldossary KM, Ali LS, Abdallah MS, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, Elmorsi YM, Kamel MM, Negm WA, Elberri AI, Hamouda AO, AlRasheed HA, Salahuddin MM, Yasser M and Hamouda MA (2024). *Front. Pharmacol.* 15:1381523. doi: 10.3389/fphar.2024.1381523

In the published article, there was an error regarding the **Affiliation** for Manal A. Hamouda. Instead of having the affiliation “7 Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt,” they should be affiliated with “9 Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Menoufia, Egypt.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.